Peptides Similar to Prostamax
Compare Prostamax with related peptides and alternatives
📌TL;DR
- •5 similar peptides identified
- •Vesugen: Both are Khavinson short bioregulator peptides. Vesugen (KED, Lys-Glu-Asp) shares the N-terminal three residues of Prostamax (KEDP).
- •Epitalon: Both are Khavinson tetrapeptide bioregulators (4 residues each). Both have acidic residues (Glu, Asp) in the middle of the sequence.
Comparison chart of Prostamax and similar peptides
Infographic pending generation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Prostamax (current) | - | - |
| Vesugen | Both are Khavinson short bioregulator peptides. Vesugen (KED, Lys-Glu-Asp) shares the N-terminal three residues of Prostamax (KEDP). | Vesugen is a tripeptide (3 residues) proposed for vascular endothelial bioregulation; Prostamax is a tetrapeptide (4 residues) proposed for prostate bioregulation. Different proposed tissue targets. |
| Epitalon | Both are Khavinson tetrapeptide bioregulators (4 residues each). Both have acidic residues (Glu, Asp) in the middle of the sequence. | Epitalon (AEDG) is proposed for pineal gland and telomerase activation; Prostamax (KEDP) is proposed for prostate. The N-terminal residue (Ala vs Lys) and C-terminal residue (Gly vs Pro) differ. |
| Vilon | Both share the N-terminal Lys-Glu motif. Both are Khavinson short bioregulators. | Vilon (KE) is a dipeptide proposed as a thymus/immune bioregulator; Prostamax (KEDP) is a tetrapeptide proposed for prostate. |
| Thymalin | Both are Khavinson-program peptide preparations. | Thymalin is a thymus-derived peptide complex (multi-component, not a single defined sequence); Prostamax is a single defined tetrapeptide. Different tissue target and different molecular nature. |
| Pinealon | Both are Khavinson short bioregulators with acidic-residue-rich sequences. | Pinealon (EDR) is a tripeptide proposed for neuroprotection; Prostamax (KEDP) is a tetrapeptide proposed for prostate. |
VesugenBoth are Khavinson short bioregulator peptides. Vesugen (KED, Lys-Glu-Asp) shares the N-terminal three residues of Prostamax (KEDP).
Differences
Vesugen is a tripeptide (3 residues) proposed for vascular endothelial bioregulation; Prostamax is a tetrapeptide (4 residues) proposed for prostate bioregulation. Different proposed tissue targets.
Advantages
Vesugen has a slightly broader citation footprint (e.g., PMID 34071923 as a co-cited compound in an Alzheimer's mouse model).
Disadvantages
Vesugen is not directly relevant to prostate-aging research; the two peptides are not interchangeable.
EpitalonBoth are Khavinson tetrapeptide bioregulators (4 residues each). Both have acidic residues (Glu, Asp) in the middle of the sequence.
Differences
Epitalon (AEDG) is proposed for pineal gland and telomerase activation; Prostamax (KEDP) is proposed for prostate. The N-terminal residue (Ala vs Lys) and C-terminal residue (Gly vs Pro) differ.
Advantages
Epitalon has a larger published literature, multiple PubMed-indexed lifespan and hTERT activation reports.
Disadvantages
Epitalon's stronger evidence base is still concentrated in the Khavinson program and lacks independent replication.
VilonBoth share the N-terminal Lys-Glu motif. Both are Khavinson short bioregulators.
Differences
Vilon (KE) is a dipeptide proposed as a thymus/immune bioregulator; Prostamax (KEDP) is a tetrapeptide proposed for prostate.
Advantages
Vilon has the most extensive published Khavinson literature.
Disadvantages
Vilon is not specifically targeted at prostate tissue.
ThymalinBoth are Khavinson-program peptide preparations.
Differences
Thymalin is a thymus-derived peptide complex (multi-component, not a single defined sequence); Prostamax is a single defined tetrapeptide. Different tissue target and different molecular nature.
Advantages
Thymalin has multi-decade clinical-use experience in Russia.
Disadvantages
Thymalin is not a defined chemical entity; cross-batch composition can vary.
PinealonBoth are Khavinson short bioregulators with acidic-residue-rich sequences.
Differences
Pinealon (EDR) is a tripeptide proposed for neuroprotection; Prostamax (KEDP) is a tetrapeptide proposed for prostate.
Advantages
Pinealon has a more developed PubMed citation footprint (multiple neuroprotection papers).
Disadvantages
Pinealon does not address prostate biology.
Similarities and differences between Prostamax and related peptides
Infographic pending generation
Peptides Similar to Prostamax (KEDP): Khavinson Bioregulator Family#
Prostamax sits within the Khavinson short-peptide bioregulator family. The closest analogues -- by sequence or by proposed mechanism -- are summarised below. The main alternative comparison set is the conventional FDA-approved BPH treatment class (alpha blockers, 5-alpha reductase inhibitors), which has incomparably more robust evidence.
Khavinson Short-Peptide Family#
| Peptide | Sequence | Length | Proposed Target Tissue | PubMed Footprint |
|---|---|---|---|---|
| Prostamax | KEDP | 4 | Prostate | 1 canonical citation (PMID 15612551) |
| Vesugen | KED | 3 | Vascular endothelium | Small; co-cited in PMID 34071923 |
| Epitalon | AEDG | 4 | Pineal gland | Largest in the family (multiple PMIDs) |
| Vilon | KE | 2 | Thymus / immune | Multiple reports |
| Pinealon | EDR | 3 | Neural tissue | Multiple PMIDs (e.g., 34071923, 22117547) |
| Thymalin | (complex) | -- | Thymus | Multi-decade clinical use in Russia |
Sequence Relatives#
Prostamax (KEDP) is closely related by sequence to:
- Vesugen (KED) -- identical first three residues
- Vilon (KE) -- identical first two residues
This suggests a possible shared N-terminal pharmacophore, although the Khavinson group's central claim is that the full sequence, including the C-terminal residue, determines tissue-selective gene-regulatory activity. There is no independent evidence that KEDP, KED, and KE behave as a single mechanistic class.
Conventional BPH Therapy Comparison#
For symptomatic benign prostatic hyperplasia, the standard pharmacological options are:
- Alpha-1 adrenergic blockers (tamsulosin, alfuzosin, silodosin) -- rapid symptom relief
- 5-alpha reductase inhibitors (finasteride, dutasteride) -- prostate-volume reduction, slower onset
- Phosphodiesterase-5 inhibitors (tadalafil) -- for overlapping ED + BPH symptoms
- Combination therapy for moderate-to-severe BPH
All of these have multi-decade randomised trial evidence, FDA labelling, and clearly characterised dose-response, side-effect, and interaction profiles. Prostamax does not have any of these. Anyone with bothersome BPH symptoms should pursue evidence-based therapy through a clinician.
Bottom Line#
Prostamax's closest peptide analogues by sequence are Vesugen and Vilon. Its closest peptide analogues by Khavinson framework are Epitalon, Pinealon, and Thymalin. None of these is an FDA-approved drug, and Prostamax has the thinnest published evidence base of the named Khavinson peptides covered on this site. Conventional BPH therapy remains the only well-evidenced choice for symptomatic prostate-aging concerns.
Related Reading#
Frequently Asked Questions About Prostamax
What's the closest Khavinson peptide to Prostamax?
Sequence-wise, Vesugen (KED, Lys-Glu-Asp) is the closest -- it shares the N-terminal three residues of Prostamax (KEDP, Lys-Glu-Asp-Pro). However, Vesugen is proposed for vascular endothelium, not prostate, so the proposed tissue targets differ.
Is Prostamax better than finasteride for BPH?
No. Finasteride and dutasteride are FDA- and EMA-approved with decades of randomised trial evidence for symptomatic BPH and prostate-size reduction. Prostamax has no comparable evidence base. The two cannot be directly compared because Prostamax lacks the trial data required for head-to-head comparison.
Can Prostamax be stacked with other Khavinson peptides?
Russian bioregulation clinics have historically combined multiple Khavinson short peptides in multi-course protocols, on the theory that each peptide acts on a different tissue. There is no PubMed-indexed evidence demonstrating safety or efficacy of any specific stack. Use of combinations multiplies the uncertainty surrounding any single peptide.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer